News

The European Society of Cardiology (ESC) and the European Respiratory Society (ERS) have published a new set of guidelines for the diagnosis and management of pulmonary hypertension (PH). These guidelines simplify diagnostic criteria for PH, emphasizing the importance of early disease detection and the expedited referral of high-risk patients…

A protein called LTBP-2 was found to be significantly elevated in people with pulmonary arterial hypertension (PAH), according to a new analysis — and the data suggest that measuring its levels may help predict long-term survival among PAH patients. Further, blood levels of LTBP-2 were also able to predict…

Measuring blood levels of a certain type of DNA released by damaged cells — called cell-free DNA — may be a way to monitor disease severity in people with pulmonary arterial hypertension (PAH), a study found. The study’s researchers from the National Institutes of Health (NIH) say the test…

Blood levels of IL-6 and PTX3 — two inflammatory proteins — could serve as prognostic biomarkers in people with pulmonary hypertension (PH) associated with left-sided heart disease, a study suggests. Higher levels of both were linked to a greater risk of dying and higher levels of NT-proBNP, a known…

More than half of babies born preterm at a center in the Netherlands were found to have pulmonary hypertension (PH), a new study reports. Babies with PH were more likely to develop bronchopulmonary dysplasia (BPD), a breathing disorder where the lungs don’t develop correctly, and survival outcomes were poorer…

Extracellular vesicles derived from mesenchymal stem cells eased the signs and symptoms of pulmonary hypertension (PH) in a rat model of bronchopulmonary dysplasia (BPD), a study shows. BPD is one of the most common complications in prematurely born infants who need supplemental oxygen and is marked by airway damage…

Treatment with Adempas (riociguat) improved blood flow measurements in people with pulmonary hypertension and heart failure with preserved ejection fraction (HFpEF) in a clinical trial. Researchers say that further study is needed to determine the effect of Adempas on clinical outcomes like exercise capacity. The study, “…

The PAH Today National Broadcast Series, created to help adults and their caregivers in the U.S. cope with pulmonary arterial hypertension (PAH), returns with two discussions for this year. Presented by the PAH Initiative and sponsored by United Therapeutics, the series offers views on contemporary approaches to managing…

Diagnostic testing plays an important role in guiding changes in treatment for children with pulmonary arterial hypertension (PAH), suggesting that virtual healthcare visits may not be an adequate substitute for in-person testing for many children with the disease. That’s according to the study, “Factors Determining Change in Treatment for…

Mixed venous oxygen tension (PvO2) — a measure for tissue oxygenation — is a significant predictor of outcomes in pulmonary hypertension (PH), a study suggested. Specifically, lower PvO2 was significantly associated with poor outcomes in people with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH),…

Elevated metabolites of the kynurenine pathway in the bloodstream of people with pulmonary arterial hypertension (PAH) when they’re diagnosed predicted disease severity, their response to therapy, and survival, a study discovered. Activation of the kynurenine pathway, related to vitamin B3 production, was found to be linked to…

Nearly a third (29.7%) of COVID-19 patients showed signs of pulmonary hypertension (PH) on an echocardiogram — a scan of heart movement — according to a study in the Netherlands. While mortality rates were significantly higher among those with suspected PH than those without it, follow-up tests suggested that…